SCHEMBL13044631

SCHEMBL13044631

O=[N+]([O-])c1cc(S(=O)(=O)Nc2ccc(Cl)c(-c3nccc4ccccc34)c2)ccc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSPD1 P10809 4/20 0.53
▸ PTPN2 P17706 4/20 0.53
▸ PTPN1 P18031 4/20 0.53
▸ PTPN5 P54829 4/20 0.53
▸ HSPE1 P61604 4/20 0.53
▸ HTR1A P08908 1/20 0.52
▸ HTR2A P28223 1/20 0.52
▸ HTR7 P34969 1/20 0.52
▸ HTR6 P50406 1/20 0.52
▸ DNMT1 P26358 1/20 0.52
▸ DNMT3A Q9Y6K1 1/20 0.52
▸ SCN9A Q15858 1/20 0.48
▸ CRHBP P24387 2/20 0.47
▸ CRHR2 Q13324 2/20 0.47
▸ SLC25A1 P53007 1/20 0.47
▸ KMT2A Q03164 2/20 0.46
▸ VCAM1 P19320 3/20 0.46
▸ HSP90AA1 P07900 2/20 0.45
▸ HSP90AB1 P08238 2/20 0.45
▸ MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13552725 0.86 HTR1A (0.69) PTPN2PTPN1PTPN5HTR1AHTR2A
SCHEMBL13552894 0.86 HTR1A (0.58) HTR1AHTR2AHTR7HTR6SCN9A
SCHEMBL13552672 0.86 HTR1A (0.53) HTR1AHTR2AHTR7HTR6SCN9A
SCHEMBL13552714 0.85 HTR1A (0.57) HTR1AHTR2AHTR7HTR6SCN9A
SCHEMBL14707324 0.84 HTR1A (0.52) HTR1AHTR2AHTR7HTR6SCN9A
SCHEMBL13552906 0.84 HTR1A (0.53) HTR1AHTR2AHTR7HTR6SCN9A
SCHEMBL13044299 0.83 CCNB2 (0.47) HTR1AHTR2AHTR7HTR6SCN9A
SCHEMBL13552903 0.83 HTR1A (0.55) HTR1AHTR2AHTR7HTR6SCN9A
SCHEMBL13554789 0.82 HTR1A (0.52) HTR1AHTR2AHTR7HTR6SCN9A
SCHEMBL13552902 0.82 HTR1A (0.51) HTR1AHTR2AHTR7HTR6SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9345699-B2 Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling NANTBIOSCIENCE, INC. (US) 2016-05-24 — — US disclosed
US-9345699-B2 Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling NANTBIOSCIENCE, INC. (US) 2016-05-24 — — US disclosed
EP-2440048-B1 ISOQUINOLINE, QUINOLINE, AND QUINAZOLINE DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING CALIFORNIA CAPITAL EQUITY LLC (US) 2015-10-07 — — EP disclosed
US-20140072630-A1 COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS ABRAXIS BIOSCIENCE, LLC (US) 2014-03-13 — — US disclosed
US-20140072630-A1 COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS ABRAXIS BIOSCIENCE, LLC (US) 2014-03-13 — — US disclosed
US-20130045240-A1 COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS ABRAXIS BIOSCIENCE, LLC (US) 2013-02-21 — — US disclosed
US-20130045240-A1 COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS ABRAXIS BIOSCIENCE, LLC (US) 2013-02-21 — — US disclosed
US-20120270858-A1 Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling CALIFORNIA CAPITAL EQUITY, LLC (US) 2012-10-25 — — US disclosed
US-20120270858-A1 Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling CALIFORNIA CAPITAL EQUITY, LLC (US) 2012-10-25 — — US disclosed
WO-2010144586-A1 ISOQUINOLINE, QUINOLINE, AND QUINAZOLINE DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING ABRAXIS BIOSCIENCE, LLC (US) 2010-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130045240-A1 COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS SHH, GLI1, SMO HSPD1 618/4885PTPN2 672/4885PTPN1 516/4885
US-20120270858-A1 Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling SHH, GLI1, SMO HSPD1 2117/4885PTPN2 1459/4885PTPN1 1889/4885
US-20140072630-A1 COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS SHH, GLI1, SMO HSPD1 618/4885PTPN2 672/4885PTPN1 516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback